MicroRNAs in cardiovascular disease: An introduction for clinicians

Heart

Volumn 101, Issue 12, 2015, Pages 921-928

  Romaine, Simon P R ^a   Tomaszewski, Maciej ^a,b   Condorelli, Gianluigi ^a,b,c   Samani, Nilesh J ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Leicester NIHR Biomedical Research Unit in Cardiovascular Disease   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 122; MICRORNA 132; MICRORNA 133; MICRORNA 133A; MICRORNA 133B; MICRORNA 145; MICRORNA 150; MICRORNA 208A; MICRORNA 212; MICRORNA 223; MICRORNA 328; MICRORNA 33A; MICRORNA 33B; MICRORNA 499; MICRORNA 499 5P; MICRORNA 622; RIBONUCLEASE; TROPONIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; MUSCLE CELL; PRIORITY JOURNAL; REVIEW; RNA ANALYSIS; VASCULAR SMOOTH MUSCLE; ADULT; ANIMAL; CARDIOVASCULAR DISEASES; GENETICS; HEART ATRIUM REMODELING; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANIMALS; ATHEROSCLEROSIS; ATRIAL REMODELING; CARDIOVASCULAR DISEASES; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY;

EID: 84930212158     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305402     Document Type: Review

References (30)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
2. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012;110:483-95.
3. Condorelli G, Latronico MV, Cavarretta E. MicroRNAs in cardiovascular diseases: current knowledge and the road ahead. J Am Coll Cardiol 2014;63:2177-87.
4. Kumarswamy R, Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013;113:676-89.
5. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012;110:496-507.
6. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15:509-24.
7. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007;116:258-67.
8. da Costa Martins PA, Bourajjaj M, Gladka M, et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008;118:1567-76.
9. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-14.
10. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008;79:562-70.
11. Carè A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-8.
12. Wahlquist C, Jeong D, Rojas-Munoz A, et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014;508:531-5.
13. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014;124:2136-46.
14. Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014;20:368-76.
15. Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012;126:S81-90.
16. Santulli G, Iaccarino G, De Luca N, et al. Atrial fibrillation and microRNAs. Front Physiol 2014;5:15.
17. Lu Y, Zhang Y, Wang N, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 2010;122:2378-87.
18. Marques FZ, Campain AE, Tomaszewski M, et al. Gene expression profiling reveals renin mRNA overexpression in human hypertensive kidneys and a role for microRNAs. Hypertension 2011;58:1093-8.
19. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009;119:2634-47.
20. Marques FZ, Booth SA, Charchar FJ. The emerging role of non-coding RNA in essential hypertension and blood pressure regulation. J Hum Hypertens 2014. Published Online First: 13 November 2014.
21. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-8.
22. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med 2015;277:260-71.
23. Zampetaki A, Willeit P, Tilling L, et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 2012;60:290-9.
24. Devaux Y, Vausort M, McCann GP, et al. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS ONE 2013;8:e70644.
25. Zampetaki A, Mayr M. Analytical challenges and technical limitations in assessing circulating miRNAs. Thromb Haemost 2012;108:592-8.
26. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011;124:1537-47.
27. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-31.
28. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011;478:404-7.
29. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-94.
30. Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005;579:5911-22.